Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Cornerstone Pharmaceuticals
- Registration Number
- NCT01520805
- Locations
- 🇺🇸
Cornerstone Pharmaceuticals, Inc, Cranbury, New Jersey, United States
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT01515527
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: triple kinase inhibitor BIBF1120
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 140
- Registration Number
- NCT01488344
- Locations
- 🇩🇪
Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Münster, Germany
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT01475370
- Locations
- 🇯🇵
National Cancer Center, Tokyo, Japan
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- Conditions
- Disorder Related to Bone Marrow TransplantationLeukemiaTransplantation Infection
- Interventions
- Procedure: Stem Cell Infusion
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 256
- Registration Number
- NCT01471444
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT01468467
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
- Conditions
- Refractory Anemia With Excess of Blasts (RAEB)Acute Promyelocytic Leukemia (APL)Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Skyline Diagnostics BV
- Target Recruit Count
- 264
- Registration Number
- NCT01463410
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸James Cancer Hospital, Columbus, Ohio, United States
🇩🇪University Hospital Ulm, Ulm, Germany
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT01451268
- Locations
- 🇩🇪
University Hospital Düsseldorf, Düsseldorf, Germany
🇩🇪University Hospital Essen, Essen, Germany
🇩🇪University Hospital Frankfurt, Frankfurt am Main, Germany
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
- Conditions
- Acute Myeloid Leukemia (AML)LeukemiaMyelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 33
- Registration Number
- NCT01442714
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Kinex Pharmaceuticals Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01397799
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States